Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD

Phathom Pharmaceuticals, Inc.

2024-Q2 EPS reported -$2.98 revenue$9,236,000

Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.
Over 122,000 cumulative prescriptions written (184% increase from 43,000); over 60,000 filled (240% from 17,500).
FDA approved VOQUEZNA 10mg for Non-Erosive GERD on July 18; commercial coverage now >116M lives (77% of US commercial).
Net loss $91.4M; non-GAAP adjusted net loss $73.3M; SG&A rose to $75.9M on launch commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.